Trio of West Coast States Announce Results from Electric Truck Charging Study

Gilead Analyst Questions Remdesivir's Ultimate Upside As Study Begins For Inhaled Version

Gilead Sciences, Inc. (NASDAQ: GILD) received FDA Emergency Use Authorization for remdesivir in early May as a treatment option for COVID-19 in adults and pediatric patients who are hospitalized with severe disease.The company has since commenced studies for an inhaled formulation of the drug.The Gilead Analyst: BofA Securities analyst Geoff Meacham maintained a Neutral rating on Gilead with an $82 price target. The Gilead Thesis: The news of Gilead kickstarting a Phase 1 study of the inhaled formulation of remdesivir in healthy volunteers this week isn't surprising, Meacham said in a Monday note. (See his track record here.)The company hinted in its first-quarter earnings call that it was investigating improved formulations of its IV drug, including subcutaneous and inhaled versions, the analyst said. Studies of the formulation in COVID-19 patients will be initiated in August, he said. "Still, we suspect the confirmation of a potential inhaled formulation is likely raising concerns...